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Fifty-nine patients with prior hepatitis B virus 
infection underwent orthotopic liver transplantation. 
During the first 2 mo, mortality was not significantly 
different in the hepatitis B virus-infected group 
(25.5%) vs. a hepatitis B virus-immune control group 
(21 %). Beyond 2 mo, the mortality, rate of graft loss, 
need for retransplantation and incidence of abnormal 
liver function were significantly higher in the hepatitis 
B virus-infected group. Treatment of the hepatitis B 
virus infection was attempted with passive immuni-
zation, combined active and passive immunization, 
a-interferon or nothing. The clinical outcome was not 
significantly influenced by any of these therapies. 
However, of the patients who lived more than 60 days, 
6 of 22 treated with active plus passive immunization 
were cleared of HBsAg, something achieved once in 16 
patients treated with a-interferon, never in 3 patients 
with passive immunization only and once in 4 patients 
with no therapy. In patients with recurrent hepatitis B 
virus infection, the pace of hepatitis development in 
the graft appeared to be accelerated, and this was 
particularly striking in patients who underwent mul-
tiple retransplantations at progressively shorter in-
tervals. None of the patients who became HBsAg-
negative had HBeAg preoperatively. (HEPATOLOGY 1991; 
13:619-626.) 
How to manage patients with HBV who undergo 
transplantation after developing end-stage chronic 
disease or fulminant hepatic failure (FHF) has been one 
of the unanswered questions in hepatology ever since it 
was realized that HBV can cause early or later graft loss 
(1, 2). Liver replacement transiently lowers the viral 
titer in the blood, as determined by serial HBsAg testing 
(1-5). However, the virus is,difficult to eradicate, almost 
ensuring that the viral infection will persist and that 
recurrent hepatitis will occur and impair the recovery 
and subsequent health of most recipients (3, 4, 6). 
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Hepatitis B hyperimmune globulin (HEla) (5-7), hepa-
titis B vaccine (HBVx) (5) and a-interferon (a-IFN) (8) 
have been administered alone or in some combination to 
such patients to prevent recurrent HBV infection in the 
new liver. The effectiveness of such therapies at clearing 
either the infection or the antigenemia is not estab-
lished. 
This study reports observations on 59 adult patients 
who had chronic or fulminant HBV infection at the time 
of liver transplantation. Follow-ups are at least 19 mo. 
We have compared the courses of those 59 recipients 
with those of 38 other patients with postnecrotic 
cirrhosis (PNC) who were HBsAg negative but whose 
serum had anti-HBs, reflecting a previous HBVinfection 
and presumed subsequent immunity. 
MATERIALS AND METHODS 
Case Material. From March 1, 1981, to February 28, 1988, 
924 consecutive patients who were at least 16 yr old 
were treated with orthotopic liver transplantation at the 
Presbyterian-University Hospital of the University of Pitts-
burgh. Throughout this time, preoperative screening for HBV 
infection was routine for all potential recipients. 
At the time of their transplantation, 38 patients were found 
to have anti-HBs but not HBsAg in their serum. These were 
designated as group 1 (HBV immune control) (Table 1). All 38 
of these patients had PNC, and 6 (15.8%) of these 38 had 
coexisting primary liver cancer (PLC). 
Fifty-nine patients who were positive for HBsAg (HBV 
infected) were the subjects of this investigation (Table 1). 
Fifty-one of the 59 had PNC as a result of the HBV infection 
(group 2); 11 (22%) of the 51 cirrhotic livers had PLC. The 
remaining eight patients had no evidence of prior liver disease 
but FHF developed from the HBVinfection (group 3). Five of 
these eight were HBV-DNA positive as determined by Abbott 
Laboratories' HBV-DNA genostics kit (Abbott Laboratories, 
North Chicago, IL); all were IgM anti-core positive at the time 
of transplantation. 
The severity of illness of each patient was defined by a 
six-tier classification system (9) that defined the distribution of 
donor livers by the United Network for Organ Sharing (UNOS) 
by urgency of need: (a) working or in school, (b) confined to 
home with self-care, (c) confined to home and requiring 
professional care, (d) hospital bound but not in an intensive 
care unit (ICU), (e) ICU bound without ventilator support and 
(f) in an ICU on a ventilator and usually unconscious. 
Differences in the general condition, performance and sex of 
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TABLE 1. Liver transplant recipients with past or present HBV infection 
Characteristics 
N 
Age (range) 
Men/Women 
Patients with tumor (%) 
Duration of disease (range) 
Urgency status (old UNOS)b 
Gastrointestinal bleeding (%) 
Encephalopathy (%) 
(Stage ~PF 
Hepatorenal (%) 
(Cr > 3 mg/dl) 
Total bilirubin (mg/dl) 
Serum albumin (gm/dl) 
Prothrombin time (sec) 
Creatinine (mg/dl) 
Group 1 
(IIBV immune) 
38 
45.6 (23.2 to 56.8) 
25/13 
6/38 (15.8%) 
7.6 yr (0.3 to 26) 
3.1 ± 1.3 
12/38 (37%) 
11/38 (29%) 
3/38 (8%) 
6.8 ± 9.1 
2.8 ± 0.4 
15.5 ± 2.1 
1.1 ± 0.5 
Values are mean ± S.D. unless otherwise stipulated. 
~ < 0.05 compared with the other two groups. 
bUNOS = United Network for Organ Sharing. 
TABLE 2. Serological profile of the 59 HBV-infected patients 
in groups 2 and 3 
Positive results 
in 45 patients 
Number of Positive who eventually 
Serological patients results survived more than 
marker tested (%) 60 days (%) 
HBsAg 59 59 (100) 45 (100) 
Anti-HBs 58 9 (15.5) 5 (11.1) 
HBeAG 56 26 (46.4) 21 (46.7) 
Anti-HBe 57 25 (43.8) 20 (44.4) 
Anti-HBc 59 59 (100) 45 (100) 
Anti-delta 55 15 (27.3) 12 (26.7) 
Not all tests were performed on every patient. 
the patients in the three groups are shown in Table 1. 
Significantly fewer women were seen in group 2 than in either 
group 1 (X2 = 6.59, p < 0.05) or group 3 <X2 = 5.81, P < 0.05). 
Most group 1 and group 2 patients were extremely ill before 
transplantation. More than 30% had a history of variceal 
bleeding, advanced encephalopathy or both. All patients in 
group 3 were in the ICU and seven of the eight had stage 3 or 
4 coma (Table 1). 
Serowgical Analysis of HBV Infection. The preoperative 
serological markers of HBV and hepatitis delta virus (HDV) 
infection are summarized in Table 2 for all 59 patients of 
groups 2 and 3. Also included is a culled tabulation of the 45 
patients from these two groups who survived at least 60 days 
after their operations (Table 2). The tests included HBsAg and 
anti-HBs, HBeAg and anti-HBe, anti-HBc and anti-hepatitis 
delta antibody (anti-HD). Commercially available RIA kits 
(Abbott Laboratories) were used for each of these determina-
tions. The same tests were performed at irregular intervals 
after transplantation. 
Operative Procedure and Immunosuppressive Regimens. 
The method of orthotopic liver transplantation has been 
standardized at the University of Pittsburgh including the use 
of a venovenous bypass (10). Immunosuppression after the 
operation consisted of cyclosporine and low maintenance doses 
Group 2 Group 3 
(IIBV infected) (IIBV fulminant) 
51 8 
46.6 (16 to 66.5) 30.6 (21 to 51.1) 
46/5a 4/4 
11/51 (21.6%) 0/8 (0) 
6.9 yr (0.5 to 22) 3.3 wk (1 to 8) 
3.4 ± 1.1 5.1 ± 1.0 
12/51 (23%) 0/8 (0) 
19/51 (37%) 7/8 (87.5%) 
4/51 (8%) 3/8 (37.5%) 
7.9 ± 12.1 21.6 ± 9.1 
2.7 ± 0.5 2.9 ± 0.5 
16.0 ± 2.9 24.3 ± 6.6 
1.2 ± 0.8 1.2 ± 0.8 
of prednisone. Injections of methylprednisolone (1 gm) or a 
5-day burst of methylprednisolone or prednisone was added 
when a rejection episode occurred. If the response to such 
"rejection" therapy was not satisfactory, the monoclonal 
antithymocyte antibody (OKT3), azathioprine or both were 
added to the immunosuppressive regimen. 
A(ijuvant Immunotherapy Used to Treat HBV Infection. 
Three different treatments were used in an attempt to 
eliminate the HBV and to avoid recurrent HBV disease. When 
HBIG (Abbott Laboratories) was used as either the sole 
therapy or in combination with Hepatavax (HBVx, Merck, 
Sharp & Dohme, West Point, PAl, 100 ml of the HBIG was 
given intravenously during the anhepatic phase of the liver 
replacement and again after concluding the operation. A third 
and final dose was given 1 mo later. For the first three cases so 
treated, 10 ml of HBIG rather than 100 ml was used at each 
time point. 
Active immunization with HBVx was attempted preopera-
tively in patients who were well enough to allow sufficient time 
for three intramuscular injections spread at monthly intervals 
before transplantation. If the patients were too ill to wait the 
necessary 2 mo, the vaccine was started after their operation. 
In either event, the vaccine was administered as a 1 ml (20 \Lg) 
dose in the deltoid muscle. 
Recombinant u-INF (Intron A; Shering Corporation, Ken-
ilworth, NJ) was administered subcutaneously at a dose of 
2.5 x 106 units/day for a minimum ,of 2 wk before and a total 
of 6 wk after transplantation. Patients with FHF were given 
HBVx or u-INF only after their operation. u-IFN therapy was 
difficult to administer, particularly before transplantation, and 
the development of hematological abnormalities often neces-
sitated a reduction in the dose used or a shortening of the 
course. 
Four patients, two in group 2 and two in group 3, were not 
treated by any of these adjuvant therapies. 
Postoperative Follow-up and Pathological Studies. When 
recipients were found to have liver function abnormalities 
after the operation, a complete workup was initiated that in 
each case included an ultrasound examination of the liver and 
its vessels, a percutaneous transhepatic cholangiogram and/or 
a needle biopsy of the liver to establish the correct diagnosis 
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TABLE 3. Patients who died or who had retransplantation 
within 60 days after liver transplantation 
Characteristic Group 1 Group 2 Group 3 
N 38 51 8 
Patients who died within 60 8 (21) 13 (25.5) 1 (12.5) 
days after transplantation (%) 
Causes 
Sepsis 5 11 0 
Pulmonary complication 0 1 0 
Myocardial infarction 0 1 0 
Death during surgery 2 0 1 
Lymphoproliferative disease 1 0 0 
Patients who had retransplan- 4 (10.5) 6 (11.8) 3 (37.5) 
tations within 60 days (%) 
Causes 
Primary graft nonfunction 3 4 2 
Hepatic artery thrombosis 1 2 1 
and treatment. All patients were observed until their death or 
to August 1989. The follow-up through August 1989 allowed 
for a minimum potential follow-up of at least 19 mo for 
patients with the most recent transplants. 
Liver biopsy specimens were obtained only for specific 
indications rather than by a set schedule. Thus the availability 
of a tissue specimen for examination implied either an 
indication for liver biopsy, retransplantation or an autopsy. All 
liver specimens were fixed in buffered formalin, embedded in 
paraffin and routinely stained with hematoxylin and eosin, 
trichrome and reticulin. In addition, expression of HBsAg and 
HBcAg by liver cells was determined routinely in these tissues 
using immunoperoxidase techniques (11, 12). 
The tissue changes of the liver in patients who experienced 
a recurrence of their viral liver disease were classified as 
follows: 0 = chronic carrier state with little or no evidence of 
hepatic damage; 1 = acute hepatitis, including examples of 
fulminant progression; 2 = the transition phase from acute 
hepatitis to CAR, defined by bridging necrosis and a transition 
from panlobular to periportal hepatocyte destruction; 
3 = CAR and 4 = cirrhosis. All histopathological samples 
were reviewed by one pathologist who did not know the clinical 
course or outcome. 
Statistical Analysis. All data are presented as mean ± S.D. 
Student's t tests and x2 tests were used for the statistical 
analyses. Patient survival was calculated using the method 
of Kaplan-Meier. Comparisons between groups were made 
by the methods of Breslow and Mantel-Cox using the 
BMDP statistical software (BMDP Statistical Software, Inc., 
Los Angeles, CAl. 
RESULTS 
Patient Survival for 60 Days. Consistent with the 
degree of patient illness, heavy mortality occurred in 
group 1 and group 2 patients within 60 days after liver 
transplantation. Eight patients (21.1%) died in group 1, 
and 13 patients (25.5%) died in group 2, after a mean 
survival time of 23. 7 ± 24.2 (S.D.) days and 29.8 ± 15.1 
(S.D.) days, respectively. The causes of these early 
deaths are shown in Table 3. No statistical differences 
existed between group 1 and group 2 in the incidence and 
causes of death within 60 days. One ofthe eight patients 
in group 3 (Table 3) died perioperatively. No patient in 
TABLE 4_ Patients who died or who had retransplantations 
60 days or later after liver transplantations 
Characteristic Group 1 Group 2 Group 3 
N 38 51 8 
Patients who continued to survive 30 (79) 38 (74.5) 7 (87.5) 
more than 60 days (%) 
Patients who died after 60 days (%) 6 15 0 
Causes 
Multiple organ failure re- O 11 0 
lated to recurrent HBV 
infection 
Multiple organ failure 3 0 0 
unrelated to recurrent 
HBV infection 
Cancer recurrence 3 3a 0 
Intracerebral bleeding 0 Ib 0 
Patients who had retransplanta- 3 7 1 
tions after 60 days (%) 
Causes 
Recurrent HBV infection 0 7 0 
Chronic rejection 2 0 Ie 
Hepatic artery thrombosis 1 0 0 
aAlI patients except one (OT #767) had CAR from recurrent HBV 
infection. 
bPatient (OT #501) who had hemophilia, had AIDS and CAR from 
recurrent HBV infection. 
ePatient (OT #788) had CAR by recurrent HBV infection but 
chronic rejection was predominant. 
groups 2 Or 3 died within 60 days because of recurrence 
of HBV. Thirteen retransplantations were performed 
during that period either because of primary graft 
nonfunction or hepatic artery thrombosis (Table 3). 
Survival after 60 Days. Twenty-four (80%) of the 30 
recipients in group 1 who survived for at least 60 days 
are still alive, with follow-ups ranging from 586 days to 
1,962 days; this is 63.2% of the original 38. Twenty-three 
(60.5%) of the 38 recipients in group 2 who lived for at 
least 60 days are still alive, with follow-ups ranging from 
518 days to 2,036 days; this is only 45.1 % of the original 
51. One of the eight patients in group 3 died during the 
operation, but the other seven are still alive 558 days to 
1,694 days after transplantation. When the survival 
rates between groups 1 and 2 were compared, patients 
with HBV infection (group 2) had a lower survival rate 
than those who were immune to the HBV (group 1) 
(p < 0.05). 
Causes of Delayed Mortality and Retransplantation. 
Reinfection by HBV ofthe new liver (Tables 4 and 5) was 
the leading cause of mortality that occurred after 60 
days. Recurrent HBV infection was an important factor 
in 11 (73%) of the 15 deaths of group 2 patients after 60 
days. Moreover, HBV infection was the exclusive reason 
for seven retransplantations in this group (Table 4). 
Four of the seven recipients who underwent retrans-
plantation died during the perioperative period of the 
second grafting, and two mOre died within 100 days from 
reCUrrence ofHBV in the second transplant. Only one of 
these seven patients is alive, and he has already required 
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TABLE 5. Influence of adjuvant therapy on HBsAG incidence of retransplantation and eventual survival of the 45 
HBV-infected patients who lived for at least 60 days after liver transplantation 
Adjuvant therapy HBIG HBIG plus HBVx IFN None 
Patients who lived more than 60 days 
HBsAg evolution 
Continuous HBsAG clearance 
N (%) 
Mean follow-up days (range) 
Transient HBsAG clearance 
N (%) 
Mean disappearance days (range) 
Mean reappearance days (range) 
Continuous HBsAG positivity 
N (%) 
Mean follow-up days (range) 
Patients who died, survived or had re-
transplantations 
Patients who had retransplantations 
N (9%) 
Mean days of retransplantation (range) 
Patients who died 
N (%) 
3 22 
0(0%) 6 (27.3%) 
1,185 (815-1,714) 
2 (66.7%) 7 (31.8%) 
21 (10-32) 43 (13-216) 
140 (26-253) 202 (86-335) 
1 (33.3%) 9 (40.9%) 
149 554 (141-1,259) 
1 (33.3%) 5 (22.7%) 
2,073 480 (203-1,293) 
3 (100%) 8 (36.4%) 
16 4 
1 (6.25%) 1 (25%) 
555 530 
2 (12.5%) 1 (25%) 
151 (137-166) 89 
257 (162-351) 260 
13 (81.3%) 2 (50%) 
591 (138-994) 609 (315-918) 
1 (6.3%) 0(0%) 
131 
3 (18.7%) 1 (25%) 
Mean days of death (range) 
Patients who surviveda 
1,033 (149-2,073) 502 (141-1,356) 292 (150-489) 305 
N (%) 0(0%) 14 (63.6%) 13 (81.3%) 3 (75%) 
Mean days follow-up (range) 1,218 (999-2,056) 698 (599-920) 726 (530-918) 
An accounting of mortality before 60 days is in Table 3. 
aBilirubin normal in all survivors. AL T and AST normal in 12 of the 30 survivors and variably elevated in the others (more than 50 to 
281 IUs). 
a third transplantation because of HBV reinfection of 
the second liver. 
Although all seven of the 60-day survivors in group 3 
are still alive, one patient has required late retransplan-
tation after 595 days because of chronic rejection plus 
HBV reinfection of her graft. 
Changes in HBV Markers in 60-day Survivors. No 
patients in group 1 became HBsAg positive at any time 
after transplantation. In the 45 patients of group 2 and 
group 3 who survived for at least 60 days, the first of the 
five HBV markers to increase after the operation was 
anti-HBs antibody. This antibody was detectable preop-
eratively in the sera of only 5 of the 45 patients studied 
(Table 2). An additional 18 patients became anti-HBs 
positive at an average postoperative time of 23.1 days 
(range = 2 to 66 days) (Fig. 1), presumably because of 
the administration of HBIG alone or HBIG plus HBVx. 
This artifact of therapy was not evident in the anti-HBe 
antibodies that did not increase (Fig. 1). During the time 
of HBIG therapy and increased anti-HBs, a decline 
occurred in HBeAg and HBsAg (Fig. 1). By about 5 mo, 
the number of patients with HBeAg had rebounded to 
the pretransplant level, the HBsAg that had cleared in 
several patients had now recurred in most and the 
anti-HBs antibodies were declining. Each of these 
changes, and all of them together, correlated well with 
the clinical diagnosis of hepatitis B recurrence (Fig. 1) 
that was made at an average of 178 ± 81 days. By 351 
days, only eight patients remained HBsAg negative. In 
the ensuing follow-up, which has been 19 mo to 57 mo 
(1,090 ± 465 [S.D.] days), none of these eight patients 
has become HBsAg positive (Table 5). 
One of the eight patients whose seroconversion to 
negative was permanent was among the 7 who survived 
more than 60 days after FHF (group 3); this was a 
surgical resident who had been infected while on duty. 
The other 7 patients who remained HBsAg negative 
were among the 38 who survived more than 60 days in 
the chronic disease group 2. 
Therapy Vs. HBV Markers. Examples of long-term 
antigen clearing occurred with two of the three 
treatment protocols and in one of four patients who had 
no treatment at all; this last patient was one of seven 
with FHF. Using the three treatment regimens, only 
HBIG plus HBVx resulted in permanent clearing of 
HBsAg in more than one patient (Table 5); 27.3% of 
patients treated with HBIG plus HBVx (6 of 22) have 
become HBsAgfree, and 6% (1 ofl6) treated with a-INF 
have become HBsAg free (Table 5). The features of all 
eight patients with permanent antigen clearing are 
summarized in Table 6. All eight were HBeAg negative 
at the time they were first seen, but six of the eight were 
HBV -DNA positive. All except one of the eight were and 
have remained anti-HBs negative. 
Among the group 2 patients with prior chronic HBV 
infection, women had a 75% (3 of 4) permanent 
conversion to HBsAg vs. 11.8% (4 of 34) for men 
(X 2 = 5.75, P < 0.05). The three women in group 2 
who became permanently negative were premenopausal 
(age 35.4, 38.8 and 47.9 yr old). The single patient with 
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TABLE 6. Features of the eight (of 45) patients with 
permanent clearing of HGsAG 
Feature 
Group 
Group 2 (chronic HBV infection) 
Women 
Men 
Group 3 (acute HBV infection) 
Women 
Men 
Treatment 
None 
HBIG 
HBIG plus HBVx 
IFN 
Preoperative markers 
HBsAG 
HBeAG 
anti-HBs 
anti-HBe 
anti-HD 
anti-HBc 
Postoperative markers 
HBsAG 
HBeAG 
anti-HBs 
anti-HBc 
anti-HBc 
All patients lived more than 60 days. 
Number 
7/38 
3/4 
4/34 
1/7 
0/3 
1/4 
1/4 
0/3 
6/22 
1/16 
8/8 
0/8 
1/8 
6/8 
4/8 
8/8 
0/8 
0/8 
3/8 
4/8 
8/8 
FHF (group 3) who became HBsAg negative was a man 
(Table 6). 
Clinicopathological Correlations. Twenty-one of the 
30 patients in group 1 who survived more than 60 days 
had biopsies done later in the course of treatment. None 
of the patients had histological or immunohistochemical 
evidence of HBV in the allograft. The biopsy findings in 
this group of patients differed markedly from those 
found in the HBV-infected groups 2 and 3. Non-B 
hepatitis was seen in seven group 1 patients. Unresolved 
lobular hepatitis was seen in two patients, and CAH 
developed in another patient. None of these patients had 
evidence of known viral liver pathogens, leading to a 
diagnosis by exclusion of non-A, non-B hepatitis. In the 
four other patients, cytomegalovirus was responsible for 
the hepatitis. None of the biopsy specimens or failed 
grafts from this group of patients was cirrhotic. 
Liver tissue was studied from 43 of the 45 patients of 
groups 2 and 3 who lived for at least 60 days. Eight 
(17.8%) of these patients (seven from group 2 and one 
from group 3) were those whose HBV markers cleared. 
Two of these recipients (OT #920 and #630) had 
elevated liver enzymes at 797 days and 829 days, 
respectively. Both patients were diagnosed as having 
non-A, non-B hepatitis because serological and histo-
pathological studies failed to reveal another cause. 
Of the 37 patients with serological evidence of HBV 
reinfection 60 days or longer after transplantation, 35 
had their diagnosis confirmed by examination of the 
liver. Two patients who were serologically HBsAg 
Anti-HBc ~ 1MM~------------------------~~~~----
., 
o 
a. 
80 
60 
/ 
HBsAG 
Clinical hepatitis 
_. __ . ___ ._ gjK!!~~KqK_K_K_K_K_K_ 
, .......... -
'" 
.::: 
OJ 
:::> 
40 "><C~K-:I~~;:;-~---
---
__ ~nti-eBs 
E 
E 
:::> 
() 
20 ,/ 
o 
....... , "~~;~~B;--D-~D:D:::D:D:~::::D~D: 
100 200 300 400 600 
Days after liver transplantation 
FIG. 1. Percentage of patients who survived more than 60 days who 
became positive as time passed for the serological or clinical param-
eters shown. Once a change to positive occurred, this was permanent 
and contributory to subsequent cumulative scores with the exception 
of the anti-HBs antibodies. The rise in anti-HBs antibodies in the first 
100 days and subsequent decline reflected HBIG administration and 
later discontinuance. 
Acute hepatitis 
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to chronic 
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FIG. 2. Summary of histopathological structure in allografts of 35 
patients who developed recurrent HBV infection after liver transplan-
tation. Note the changes in histopathological classification that 
occurred in many of the recipients who had serial biopsies. 
positive refused biopsy. One (OT #955) had normal 
liver function, whereas the other (OT #914) had 
abnormal function. 
In those four patients of groups 2 and 3 who had 
retransplantation because of recurrence of HBV and 
who survived retransplantation, recurrence was diag-
nosed in the second grafts at 68, 87, 89 and 178 days. 
Three ofthese four patients always had HBeAg-positive 
sera, and all four had unrelieved HBsAg positivity. 
Recurrence of HBV infection occurred faster with the 
second transplantation than after primary liver re-
placement. One patient (OT # 528) died after 104 days 
with massive hepatic necrosis, a second (OT #869) died 
after 99 days with recurrent acute hepatitis and multiple 
organ failure and the remaining two (OT #539 and 
# 788) are alive but with CAH after 128 days and 395 
days, respectively. 
By reviewing specimens from the foregoing 35 pa-
tients with HBV reinfection, it was possible to recon-
struct a progression of pathological changes of recurrent 
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FIG. 3. Evolution of histopathological changes in serial liver biopsies of patient OT #810 with recurrent HBV-induced cirrhosis. (a) At 71 
days, mild spotty hepatocyte necrosis was seen. PT = portal tract. (H & E, original magnification x 300). (b) At 147 days, features of acute 
hepatitis were evident, superimposed on bridging and piecemeal necrosis (arrow), that were suggestive of a transition to chronic hepatitis with 
progression (H & E, original magnification x 300). (c) At 187 days, early regenerative nodule formation was already present (H & E, original 
magnification x 300). (d) At 203 days, failed graft removed at retransplantation that showed well-developed cirrhosis (H & E, original 
magnification x 100). 
HBV (Fig. 2). The first histological sign of recurrent 
HBV infection, as early as 2 wk to 5 wk after transplan-
tation, was the presence of HBcAg in the cytoplasm of 
the homograft hepatocytes. Usually, little other evi-
dence of pathological changes in the liver was seen at this 
time. After 70 days to 298 days (average = 151) days, 
mild lobular disarray, hepatocellular swelling, mild 
spotty acidophilic necrosis and regenerative changes 
signaled the onset of hepatitis activity in 21 patients. 
The changes in most of these specimens were similar to 
those seen in nonimmunosuppressed patients with 
HBV, but lobular or portal inflammation was less. The 
usual pathological diagnosis was mild acute hepatitis. 
At an average of 242.2 days (range = 117 days to 567 
days), 11 patients showed transitional change from 
acute hepatitis to CAR. The transition was charac-
terized by the appearance of bridging necrosis and 
predominantly periportal hepatocyte destruction. This 
was in contrast to the panlobular activity observed 
during the acute phase. By 128 days to 1,140 days, 17 
patients had established CAR. Finally, five patients had 
cirrhotic grafts at 203 days to 2,054 days (aver-
age = 912.8 days). 
When biopsy specimens were obtained frequently, it 
was possible to see these stages evolve in a single graft 
(Fig. 2). Patient OT #810 was found to have acute 
hepatitis at 71 days, a transitional form of hepatitis at 
147 days, CAR at 187 days and cirrhosis at 203 days (Fig. 
3). This patient, who was treated with HBIG plus HBVx, 
also had PLC that recurred. He died shortly after the 
retransplantation procedure. 
A clinical syndrome of FHF developed in three 
patients from 5 to 12 mo after transplantation. Only one 
of the three (OT # 528) had a liver with the typical 
histological picture of massive hepatic necrosis and 
marked inflammation. The grafts in the other two 
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showed marked hepatocellular ballooning with focal 
bridging necrosis in the absence of significant hepatic 
inflammation. However, a striking expression of HBcAg 
by the hepatocytes was seen (Fig. 4). 
Five other patients had grafts with a histological 
pattern resembling a chronic carrier state with the 
typical ground glass appearance of the hepatocytes but 
little evidence of inflammation. These patients were 
exclusively in the subgroup given a-IFN therapy (Table 
5). The presence of anti-delta agent antibodies did not 
predictably alter the histopathological findings. 
Current Hepatic Function. All but 1 (OT #372) of the 
24 patients who are alive in group 1 have no significant 
abnormality of hepatic function. In contrast, only 12 of 
the 30 patients who are alive in groups 2 and 3 have 
perfect graft function (Table 5). Patients who were 
treated by a-IFN tended to have worse liver function 
than those given HBIG plus HBVx (x2 = 3.41), although 
five patients treated with a-IFN had a reassuring 
histopathological figure resembling that seen with the 
chronic carrier state. 
DISCUSSION 
The observations in these patients confirm previous 
reports (2-7) that the prognosis after transplantation is 
poor for recipients with persistent HBV infection. It is 
not known whether therapy with active immunization, 
HBIG or a-IFN can improve the outlook. The most 
optimistic reports of therapy have come from Hanover, 
Germany, (5), where active and passive immunization 
have been combined, as we did in one of our therapeutic 
subgroups. 
The development and progression of recurrent HBV 
disease was slow enough so that many of our patients 
experienced prolonged rehabilitation before some 
variant ofthe disease that had destroyed the native liver 
was repeated. Even so, the pace was considerably faster 
than that occurring with the naturally acquired in-
fection, which was determined by the pretransplant 
medical history of these same individuals. In patients 
who underwent a second retransplantation, the second 
graft was even more vulnerable than the first trans-
plant, which was determined by the time required to 
manifest graft failure or cirrhosis. These findings in 
patients under effective immunosuppression are not 
congruent with hypotheses that the principal damage in 
HBV hepatitis is by way of an autoimmune mechanism 
or that the HBV is not cytopathic. 
The most encouraging observation from this study is 
that the HBV could be cleared, as determined by HBsAg 
positivity, in about one of every six patients. It should be 
noted that all eight patients who converted to HBsAg 
negativity were HBeAg negative before transplantation, 
suggesting a low rate of viral replication even though six 
of these eight patients were HBV-DNA positive. 
Six of the eight patients who cleared their HBsAg had 
been treated with HBIG plus active immunization with 
HBVx, one was given a-IFN and one (with FHF) 
converted to negative HBsAg with no treatment at all. 
a-IFN was not efficacious, contrary to our hopes, which 
FIG. 4. Failed allograft removed at 378 days in a patient who had 
subacute hepatic failure. (a) Very little inflammation but marked 
hepatocellular swelling and degeneration in the centrilobular regions. 
Bridging (arrow) between central veins and between portal and central 
veins was seen. PT = portal tract, CV = central vein. (H & E, original 
magnification x 300). (b) Tissue expression of HBcAg. This was most 
intense and largely restricted to the degenerating hepatocytes, where 
both nuclear and cytoplasmic core antigen were detected (immuno-
peroxidase stain for HBcAg, original magnification x 120). 
were based on a-IFN's effectiveness in nontransplant 
settings (13-15). The fact that continuous immunosup-
pression was required to prevent graft rejection in these 
cases may have accounted for the poor outcome with 
IFN therapy. 
No conclusions are warranted from this study about 
the efficacy of the therapies that were tried. Instead, the 
results emphasize the difficulties of the management 
problems that were frequently encountered long after 
transplantation. However, the possibility cannot be 
excluded that combined active plus passive immuni-
zation or better designed a-IFN therapy might allow a 
significant number oflong-term serological conversions. 
This possibility should stimulate additional trials with 
even more intensive immunization or therapeutic 
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schedules. In addition, passive immunization may 
become more effective by using the anti-HBs monoclonal 
antibodies that have been produced by Ostberg and 
Pursch (16) from a complex hybridoma that produces 
human IgG. These hybridoma immunoglobulins are 
nearly 50,000 times more potent than the best currently 
available immunoglobulin preparations. Preliminary 
encouraging but inconclusive trials with such reagents 
have been reported (17) and are still in progress; these 
cases were not part of this report. 
Another unknown factor in future trials could be 
improved immunosuppression. The new drug FK 506, 
which is having its first clinical trials (18), can be used 
with very low or no steroid doses. When used alone, FK 
506 does not reduce the number or function of natural 
killer cells that are important in viral immunity (19). In 
addition to this potential advantage, FK 506 has been 
shown in experimental models to stimulate or promote 
hepatic regeneration and repair (20). Such consider-
ations and the possibility of better immunoprophylaxis 
justify continued efforts to use transplantation in 
treating these difficult cases. 
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